[go: up one dir, main page]

DK0574487T3 - Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B - Google Patents

Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B

Info

Publication number
DK0574487T3
DK0574487T3 DK92906520T DK92906520T DK0574487T3 DK 0574487 T3 DK0574487 T3 DK 0574487T3 DK 92906520 T DK92906520 T DK 92906520T DK 92906520 T DK92906520 T DK 92906520T DK 0574487 T3 DK0574487 T3 DK 0574487T3
Authority
DK
Denmark
Prior art keywords
hepatitis
treatment
thiacytidine
deoxy
fluoro
Prior art date
Application number
DK92906520T
Other languages
English (en)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
George Robert Painter Iii
Phillip Allen Furman
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of DK0574487T3 publication Critical patent/DK0574487T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK92906520T 1991-03-06 1992-03-05 Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B DK0574487T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
PCT/GB1992/000388 WO1992015308A1 (en) 1991-03-06 1992-03-05 Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b

Publications (1)

Publication Number Publication Date
DK0574487T3 true DK0574487T3 (da) 2002-10-14

Family

ID=26298535

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92906520T DK0574487T3 (da) 1991-03-06 1992-03-05 Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
DK01202860T DK1142891T3 (da) 1991-03-06 1992-03-05 Salte og amider af (-)cis-5-fluor-2'-deoxy-thiacytidin der er egnede til behandling af hepatitis B

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01202860T DK1142891T3 (da) 1991-03-06 1992-03-05 Salte og amider af (-)cis-5-fluor-2'-deoxy-thiacytidin der er egnede til behandling af hepatitis B

Country Status (21)

Country Link
EP (3) EP1808434A3 (da)
JP (5) JP3479068B2 (da)
KR (1) KR100270806B1 (da)
AT (2) ATE219366T1 (da)
AU (1) AU662130B2 (da)
CA (1) CA2105486C (da)
CZ (1) CZ282747B6 (da)
DE (2) DE69233693T2 (da)
DK (2) DK0574487T3 (da)
ES (2) ES2286072T3 (da)
HU (1) HUT64844A (da)
IE (1) IE920701A1 (da)
IL (1) IL101144A (da)
MX (1) MX9203213A (da)
NZ (1) NZ264621A (da)
PT (1) PT100198B (da)
RU (1) RU2116789C1 (da)
SK (1) SK279542B6 (da)
TW (1) TW201268B (da)
UA (1) UA54364C2 (da)
WO (1) WO1992015308A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674634B1 (en) * 1989-02-08 2003-04-16 Biochem Pharma Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
ES2286072T3 (es) * 1991-03-06 2007-12-01 Emory University Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171550C (en) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
WO2000009531A2 (en) 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CN1141305C (zh) 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
RU2237479C2 (ru) * 1998-11-05 2004-10-10 Сантр Насьональ Де Ля Решерш Сьентифик Нуклеозиды, обладающие активностью против вируса гепатита в
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
BR0314259A (pt) 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196607B (en) * 1985-05-15 1988-12-28 Wellcome Found Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
JPH04501854A (ja) 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
ES2286072T3 (es) * 1991-03-06 2007-12-01 Emory University Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.

Also Published As

Publication number Publication date
JP2002220388A (ja) 2002-08-09
DE69233693D1 (de) 2007-06-14
IE920701A1 (en) 1992-09-09
IE20040402A1 (en) 2007-10-17
JP4399478B2 (ja) 2010-01-13
AU662130B2 (en) 1995-08-24
IL101144A0 (en) 1992-11-15
JPH06505725A (ja) 1994-06-30
KR100270806B1 (ko) 2000-11-01
PT100198A (pt) 1993-05-31
RU2116789C1 (ru) 1998-08-10
WO1992015308A1 (en) 1992-09-17
CA2105486A1 (en) 1992-09-07
JP2010013466A (ja) 2010-01-21
HUT64844A (en) 1994-03-28
EP0574487B1 (en) 2002-06-19
DE69232649D1 (de) 2002-07-25
MX9203213A (es) 1992-07-01
JP3987335B2 (ja) 2007-10-10
ATE219366T1 (de) 2002-07-15
TW201268B (da) 1993-03-01
IL101144A (en) 1996-09-12
EP1142891A1 (en) 2001-10-10
DE69233693T2 (de) 2008-01-24
ATE361293T1 (de) 2007-05-15
EP1808434A2 (en) 2007-07-18
DE69232649T2 (de) 2002-11-28
SK95093A3 (en) 1994-04-06
CZ282747B6 (cs) 1997-09-17
UA54364C2 (uk) 2003-03-17
SK279542B6 (sk) 1998-12-02
ES2286072T3 (es) 2007-12-01
HU9302493D0 (en) 1993-11-29
EP1142891B1 (en) 2007-05-02
JP4891435B2 (ja) 2012-03-07
ES2179040T3 (es) 2003-01-16
DK1142891T3 (da) 2007-08-27
EP1808434A3 (en) 2008-04-02
JP2011102308A (ja) 2011-05-26
CZ183593A3 (en) 1994-04-13
PT100198B (pt) 2000-03-31
CA2105486C (en) 2003-10-28
AU1367692A (en) 1992-10-06
EP0574487A1 (en) 1993-12-22
JP2007246536A (ja) 2007-09-27
JP3479068B2 (ja) 2003-12-15
NZ264621A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
DK0574487T3 (da) Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
EE02995B1 (et) 1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
GB9110874D0 (en) Medicaments
FI933684A0 (fi) Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution
DK224286D0 (da) 2',3'-dideoxy-nucleosider
MY109796A (en) 1,3-oxathiolane nucleoside analogues.
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
ATE185483T1 (de) Antivirale nucleosidkombination
MY137298A (en) Therapeutic nucleosides
DK1115420T3 (da) Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
DK0388049T3 (da) Penciclovirderivater til behandling af hepatitis B infektioner
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
SE9602262D0 (sv) New use of derivatives of cystine